Marksans Pharma Ltd (NSE:MARKSANS)
₹ 168.45 -0.6 (-0.35%) Market Cap: 76.34 Bil Enterprise Value: 70.73 Bil PE Ratio: 23.83 PB Ratio: 4.01 GF Score: 83/100

Q3 2023 Marksans Pharma Ltd Earnings Call Transcript

Feb 14, 2023 / 10:00AM GMT
Release Date Price: ₹68.65 (+3.86%)
Unidentified Company Representative

Good evening, everyone, and a warm welcome to Marksans Pharma's Q3 and nine-months FY23 earnings call. (Operator Instructions) The results, press release, and investor presentation are available on the stock exchanges and company website.

I would like to now introduce the management team today on the call with us: Mr. Mark Saldanha, Founder, Chairman, and Managing Director; and Mr. Jitendra Sharma, Chief Financial Officer. A cautionary note that some of the statements made on today's call could be forward-looking in nature and actual results could vary from these statements. A detailed intimation in this regard is available in the Investor Presentation, which is available on the stock exchanges and the company's website.

I will now hand over the call to Mr. Mark Saldanha for the highlights. Over to you, sir.

Mark Saldanha
Marksans Pharma Ltd - Founder, Chairman & MD

Thank you, Siddharth. Welcome, everyone, and thank you for joining us on our Q3 FY23 and nine-month FY23 earning conference call. I'm pleased to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot